Detail akcie Novartis AG Depository Receipt online

Business Summary: Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Novartis AG (ADR) revenues increased 8% to $46.66B. Net income before extraordinary items increased 42% to $8.57B. Revenues reflect United States segment increase of 13% to $17.96B, China segment increase of 11% to $3.27B. Net income benefited from Research & Development - Balancing value decrease of 8% to $8.6B (expense), Restructuring Charges decrease of 36% to $1.18B (expense).